Clinical Trial Search

Primary: Percentage of Participants With Kaplan-Meier Curve Progression Free Survival (PFS) Constructed With an 95% Confidence Interval — 100; 82.1; 71.0 percentage of participants

Primary: Complete Remission Rate: Percentage of Participants With Complete Remission (CR) — 85 percentage of participants

Primary: Complete Response Rate — 83 percentage of participants

Primary: Overall Survival (OS) at 1 Year — 1.0; 0.82 Cumulative proportion surviving at 1 yr

Primary: Overall Response Rate — 11; 2 Participants

Primary: Participants With a Response — 9 Participants

Primary: Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen — 100; 100; 100; 100 percentage of patients

Primary: Complete Remission — 10 participants

Primary: Overall Response Rate (ORR) as Determined by Local Investigator — 32.1 Percentage of participants

Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients

Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035

Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…

Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants

Primary: Grade ≥ 3 Stomatitis — 4; 6; 41; 34 participants

Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…

Primary: 3-Year Event-Free Survival (EFS) — 68 Participants

Primary: Event-free Survival — 88; 82; 80; 63 percentage of particpants — p=.97

Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants

Primary: Event-free Survival Probability by Risk Group — 0.886; 0.844; 0.667; 0.793 probability of 5 yr. event free survival

Primary: Protocol Compliance as Measured by Percent Compliance to Prescribed Chemotherapy — 73.8; 96.0; 50.0; 74.9 percentage of compliance — p=<0.001

Primary: Objective Response Rate — 0 percentage of participants

Primary: Progression-free Survival — 89 percentage of participants

Primary: Median Progression Free Survival (PFS) — 13.8 years

Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients

Primary: Event-Free Survival (EFS) — 87.0 Percent probability

Primary: 3-year Event-Free Survival Probability — 0.887 probability — p=0.9970

Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…

Primary: Grades of Toxicity by Type of Toxicity — 2; 2; 1; 1 toxicities

Primary: Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization — 95.05; 94.17 percent probability

Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants